Small-Molecule Transcription Factor Inhibitors in Oncology [Hardcover]

Oncogenic transcription factors are an increasingly important target for anticancer therapies. Inhibiting these transcription factors could allow tumour cells to be reprogrammed , leading to apoptosis or differentiation from the malignant phenotype. As the use of kinase inhibitors is gradually declining, transcription factor inhibition is the next hot topic for oncology research and merits much attention. This book highlights recent progress in the development of small-molecule inhibitors of oncogenic transcription factors. It also presents the evidence that this important protein class can be modulated in a number of ways to develop novel classes of therapeutic agents. The broad range of aspects covered by the book is noteworthy and renders it enormously valuable. This title serves as a unique reference book for postgraduates, academic researchers and practitioners working in the fields of biochemistry, biotechnology, cell and molecular biology and bio-inorganic chemistry.This title highlights recent progress in the development of small-molecule inhibitors of oncogenic transcription factors. It also presents the evidence that this important protein class can be modulated in a number of ways to develop novel classes of therapeutic agents for anticancer treatments. This book is a unique reference book for postgraduates, academic researchers and practitioners working in the fields of biochemistry, biotechnology, cell and molecular biology and bio-inorganic chemistry.Preface: Small Molecule Transcription Factor Inhibitors; Synthetic Approaches and Challenges Towards Transcription Factor Inhibitors; Computational Approaches in the Development of Small Molecule Transcription Factor Inhibitors; Natural Products as Promising Leads Against Oncogenic Transcription Factors and Associated Signalling Pathways; Pyrrolobenzodiazepines as Transcription Factor Inhibitors: An Overview; Small Molecule Inhibitors of NF-kB and Their Therapeutic Potential in Leukaemia; Targeting Signall³&